Top Markets
#1 DogBull DogBull +105.34%
#2 ADO Protocol ADO Protocol +49.93%
#3 Siacoin Siacoin +47.29%
#4 MarsCoin MarsCoin +42.19%
#5 UnifAI Network UnifAI Network +39.96%
#6 Useless Coin Useless Coin +30.85%
#7 Ontology Gas Ontology Gas +23.69%
#8 Magma Finance Magma Finance +21.84%
#9 Filecoin Filecoin +15.49%
#10 Apertum Apertum +13.01%
Coin of the day
DogBull DogBull
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Hansa Biopharma AB Hansa Biopharma AB

Hansa Biopharma AB

HNSBF
Classificação em ações #15153
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Preço da ação
$3.70
Última sincronização: 2026-08-31
Valor de mercado
$369.01M
Variação (1 dia)
0.00%
Variação (1 ano)
35.04%
País
SE
Negociar Hansa Biopharma AB (HNSBF)

Categoria

Healthcare
Histórico de dividendos de Hansa Biopharma AB (HNSBF)
Hansa Biopharma AB (símbolo da ação: HNSBF) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de Hansa Biopharma AB (HNSBF) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
23.00%
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
0.00%
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
0.00%
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
0.00%
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
0.00%
US